A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Conditions: Advanced Solid Tumors; Advanced or Metastatic Gastric Cancer; Advanced or Metastatic Gastroesophageal Junction Cancer Intervention: Drug: MRG002 Sponsor: Shanghai Miracogen Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Research | Study